Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
TTE heads into its October 29 results with the lending market exceptionally loose, short positioning near a year-low, and the stock quietly lagging its European peers across every timeframe this week.
The borrow story here is striking in its tranquility. Availability is running at roughly 2,321%, meaning there are more than 23 shares available to lend for every one already borrowed. That is well above the 52-week floor of 1,281% and has widened further over the past week, rising around 7%. The borrow rate ticked up to 1.56% on October 7, roughly double where it was a week prior, but remains low in absolute terms and the month-long trend is still a sharp drop from the 2.43% level seen at the end of September. There is simply no evidence of squeeze pressure or a crowd building short positions: the ORTEX short score has drifted between 31 and 34 over the past two weeks, placing TTE in the lower half of the universe at a rank of 56 on the percentile scale.
Analyst sentiment points firmly higher, though it comes with a valuation gap worth flagging. The consensus price target of €99.05 against a close of €75.42 implies roughly 31% potential upside. No recent rating changes appear in the data, so the gap reflects accumulated longer-run optimism rather than a fresh catalyst. On valuation, TTE trades at a price-to-earnings ratio of 7.6x, an EV/EBITDA of 4.6x and a price-to-book of 1.38x, all at the cheaper end of the integrated energy peer group. The earnings yield factor scores in the 72nd percentile on EV/EBIT, and the dividend score sits in the 94th percentile, a signal that income-oriented capital continues to regard the stock favourably. EPS momentum over 30 days ranks in the 84th percentile, though the 90-day read is a more middling 51 and the 12-month forward earnings growth estimate has been negative, which caps the enthusiasm on the growth side.
A small cluster of insider subscriptions hit the tape across October 2 to 6, with executive committee members including Stoquart, Hamelle, Michel and Pinatel all taking fractional share purchases at prices between €74.46 and €75.80. The trades are tiny in scale and appear to be linked to a share savings plan rather than discretionary buying. Net insider activity over the past 90 days rounds to zero. Amundi remains the largest external 13G filer, reporting a stake of around 9.0% as of July 22, down slightly from 9.4% previously. Stakes are as-last-disclosed and Amundi could have moved since filing.
The most recent earnings print is instructive for context. On September 28 TTE fell 2.4% on the day and lost 5.2% across the following five sessions. The July 23 print was the opposite: a 2.2% gain on the day that held into the week. That asymmetry, one clean beat followed by a punished miss, is the pattern going into the next event. Peers have outperformed this week. SHEL gained 2.2% and BP. rose 2.3% over seven days. ENI added 0.9%. TTE's flat-to-down week, off 0.37% over seven days to €75.42, places it at the bottom of the group.
With Q3 results on October 29 and 21 days to the print, the stock's positioning offers no obvious directional lean. What the next three weeks will reveal is whether the upstream production beat flagged in September commentary translates into cash generation numbers strong enough to close the gap between the current price and where the Street has been anchoring targets.
See the live data behind this article on ORTEX.
Open TTE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
